KITLG and inflammatory bowel disease: The phenomenon of a dramatic decrease in KIT immunoreactivity coupled to an increase in total mast cell numbers was already shown in IC and inflammatory bowel disease patients (Pang et al. 1998; Farhadi et al. 2007), and was explained by internalization of KIT upon binding of its ligand SCF (Shimizu et al. 1996).